HkeyBio Launches Comprehensive Autoimmune Disease Model Platform for Drug Development
Key Insights
HkeyBio (search) announced the launch of standardized preclinical disease model platforms covering autoimmune hepatitis (search), primary biliary cholangitis (search), and IgA nephropathy (search) to support global drug R&D institutions.
The platform integrates rodent models with non-human primate research capabilities to enable efficacy evaluation, mechanistic studies, and biomarker development for autoimmune diseases.
The initiative addresses significant translational gaps in preclinical research, where traditional single-disease models cannot fully satisfy complex mechanism research needs for cross-organ immune therapies.
HkeyBio (search) announced the launch of preclinical disease model platforms covering Autoimmune Hepatitis (search) (AIH), Primary Biliary Cholangitis (search) (PBC), and IgA Nephropathy (search) (IgAN). The platform integrates standardized rodent models with continuously developing non-human primate research capabilities, aiming to support global innovative drug R&D institutions in conducting efficacy evaluation, mechanistic studies, biomarker development, and cross-species translational research.
The announcement comes as autoimmune diseases continue to be a critical direction for global pharmaceutical innovation, with R&D institutions seeing increasing demand for disease models with clinical relevance and translational predictive capabilities. Disease heterogeneity, long-term disease courses, and complex immune mechanisms pose significant challenges to preclinical research, particularly in autoimmune liver diseases and immune-mediated nephropathies.
Addressing the Translational Gap in Autoimmune Drug Development
Over the past decade, global R&D in autoimmune diseases has expanded beyond traditional TNF-α (search), IL-17 (search), and IL-23 (search) pathways to include new mechanisms such as APRIL (search), BAFF (search), the complement system, FcRn (search), TYK2 (search), and immune tolerance reconstruction. An increasing number of R&D projects are adopting the "One Molecule, Multiple Indications" strategy, covering diseases of multiple organ systems through shared immune mechanisms.
Industry research indicates that a significant translational gap still exists between preclinical research results and clinical benefits. The FDA, EMA, and ICH have continuously encouraged improvement of clinical predictive capabilities and R&D efficiency through biomarkers, pharmacologically relevant models, and translational research strategies.
HkeyBio (search) management stated: "As autoimmune disease drug R&D gradually shifts from single indications toward cross-organ immune mechanism research, the demand from R&D teams for high-translational-value disease models continues to rise. More and more innovative therapies are simultaneously focusing on the interactions among the liver, kidneys, intestines, and the systemic immune system. Traditional single-disease models can no longer fully satisfy the needs of complex mechanism research and clinical translation."
Disease-Specific Challenges and Opportunities
Autoimmune Hepatitis: Growing Global Burden
Autoimmune Hepatitis (search) is a chronic inflammatory liver disease caused by an imbalance in immune tolerance. A global systematic review published in The Lancet Gastroenterology & Hepatology shows that the global prevalence of AIH is approximately 15.65 per 100,000 people, showing a continuous upward trend over the past decades.
Although glucocorticoids (search) combined with azathioprine remain the first-line treatment recommended by international guidelines, issues such as long-term relapse risks, drug toxicity, and insufficient response in some patients persist. Novel therapeutic strategies centered on B cell regulation, T cell immune tolerance reconstruction, and inflammatory pathway modulation are continuously advancing.
Primary Biliary Cholangitis: Focus on Fibrosis Reversal
Primary Biliary Cholangitis (search) is a chronic cholestatic autoimmune liver disease. In recent years, innovative therapies such as PPAR agonists (search) and FXR modulators (search) have successively received regulatory approval, providing patients with new treatment options. However, disease progression, bile duct injury, liver fibrosis, and symptom control remain significant challenges in current drug R&D.
IgA Nephropathy: Mechanism-Directed Therapy Era
IgA Nephropathy (search) is one of the most common primary glomerular diseases globally. The currently widely accepted "Multi-Hit Hypothesis" posits that the formation of galactose-deficient IgA1 (search) (Gd-IgA1) and the deposition of its immune complexes constitute the core mechanism of disease onset and progression.
Recent sustained progress has been made in APRIL (search) inhibitors, BAFF (search) modulators, complement inhibitors, and intestinal mucosal immunomodulatory therapies, making IgAN one of the most active fields in global kidney disease R&D.
Platform Capabilities and Technical Specifications
Despite continuous development of organoids, organs-on-chips, and AI-assisted R&D, animal models remain a crucial bridge connecting basic research and clinical development. Current model limitations include difficulty in stably reproducing chronic disease progression in AIH models, limitations in simulating disease heterogeneity and fibrosis in PBC models, and structural differences in IgA between humans and rodents affecting IgAN models.
HkeyBio (search) has established a standardized disease model system addressing these challenges through optimization of animal strain selection, disease induction protocols, pathological evaluation systems, biomarker systems, experimental quality control standardization, and systematic research.
The platform currently supports drug candidate screening, pharmacodynamic evaluation, mechanistic studies, biomarker development, dose exploration, and combination therapy research.
Non-Human Primate Research Development
HkeyBio (search) is continuously advancing the development of NHP research systems related to AIH, PBC, and IgAN. Non-human primates share high similarity with humans in immune system composition, genomic structure, and pharmacokinetic profiles, possessing significant translational value in the development of innovative biologics.
The NHP platforms are expected to support PK/PD evaluation, humanized antibody research, biomarker monitoring, immunogenicity evaluation, clinical dose prediction, and IND-enabling studies.
Comprehensive R&D Chain Integration
By integrating the rodent model platform with NHP research capabilities, HkeyBio (search) is building a complete R&D chain spanning target validation, candidate molecule screening, efficacy evaluation, mechanistic studies, biomarker development, translational research, and IND support.
The company aims to improve the translational predictive capability of preclinical research to help partners optimize R&D decision-making, reduce development risks, and drive innovative therapies into the clinical phase more efficiently.
HkeyBio (search) is a preclinical Contract Research Organization focused on autoimmune and inflammatory diseases, providing in vivo efficacy evaluation and translational medicine research services to global biotechnology companies, pharmaceutical enterprises, and research institutions. The company possesses capabilities encompassing rodent models, non-human primate research platforms, pharmacodynamic evaluations, biomarker analysis, and IND-enabling studies.